IO Biotech, Inc.
IOBT
$0.98
-$0.04-3.92%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.62% | 8.53% | 6.30% | -2.29% | 7.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.40% | 12.86% | -1.46% | 12.68% | 38.23% |
| Operating Income | 4.40% | -12.86% | 1.46% | -12.68% | -38.23% |
| Income Before Tax | -19.59% | -7.63% | 1.62% | -14.45% | -35.34% |
| Income Tax Expenses | 26.06% | 147.61% | -29.70% | 2.22% | -64.24% |
| Earnings from Continuing Operations | -19.67% | -10.78% | 2.32% | -14.16% | -30.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.67% | -10.78% | 2.32% | -14.16% | -30.45% |
| EBIT | 4.40% | -12.86% | 1.46% | -12.68% | -38.23% |
| EBITDA | 4.43% | -12.86% | 1.51% | -12.63% | -38.43% |
| EPS Basic | -19.68% | 15.64% | 57.28% | 50.08% | 42.94% |
| Normalized Basic EPS | -19.59% | 18.04% | 56.97% | 49.96% | 40.81% |
| EPS Diluted | -19.68% | 15.64% | 57.28% | 50.08% | 42.94% |
| Normalized Diluted EPS | -19.59% | 18.04% | 56.97% | 49.96% | 40.81% |
| Average Basic Shares Outstanding | 0.00% | 31.32% | 128.63% | 128.63% | 128.63% |
| Average Diluted Shares Outstanding | 0.00% | 31.32% | 128.63% | 128.63% | 128.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |